Table 3.
Amount of Chemotherapy, Dose Reductions and Delays, Renal Function Assessment, and Growth Factor Use
| Variable | GC(n = 88) |
M-CAVI(n = 87) |
||
|---|---|---|---|---|
| No. | % | No. | % | |
| Chemotherapy cycles | ||||
| Median | 4.5 | 3 | ||
| Range | 1-10 | 1-23 | ||
| > Six cycles | 11 | 12.4 | 5 | 5.7 |
| Reason for dose reductions | ||||
| Any | 63 | 71.6 | 73 | 83.9 |
| Hematologic | 43 | 48.9 | 48 | 55.2 |
| Renal | 7 | 8.0 | 13 | 14.9 |
| Reason for dose delay | ||||
| Any | 67 | 76.1 | 53 | 60.9 |
| Hematologic | 32 | 36.4 | 33 | 37.9 |
| Renal | 4 | 4.5 | 1 | 1.1 |
| GFR, calculated at least once | ||||
| Calculated | 78 | 88.6 | 78 | 89.7 |
| Measured | 3 | 3.4 | 5 | 5.7 |
| EDTA | 6 | 6.8 | 3 | 3.4 |
| GCSF, secondary prophylaxis | 5 | 5.6 | 10 | 11.4 |
Abbreviations: GC, gemcitabine/carboplatin; M-CAVI, methotrexate/carboplatin/vincristine; GFR, glomerular filtration rate; EDTA, ethylenediaminetetra-acetate; GCSF, granulocyte colony-stimulating factor.